Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS and BBDF obtain European "orphan medicinal product" designation for BBDF-101 in Batten disease

21/10/2020
Download PDF File (290Ko)

THERANEXUS publishes its cash position as of 30 September 2020

15/10/2020
Download PDF File (1328Ko)

THERANEXUS announces its first half 2020 results

29/09/2020
Download PDF File (767Ko)

THERANEXUS presents its latest scientific news

09/09/2020
Dowload PDF File (711Ko)

THERANEXUS and BBDF obtain orphan drug designation (ODD) and Rare Paediatric Disease Designation (RPDD) from the Food And Drug Administration (FDA) for BBDF-101 for Batten disease

11/08/2020
Dowload PDF File (390Ko)